Entospletinib
As of the edition of 20 October 2026, Entospletinib is a small molecule: stopped in 2024; acts on SYK.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 14, 10 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Entospletinib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SYK | Tyrosine-protein kinase SYK | P43405 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 9 | 2 | 0 | 7 |
| Phase 3 | 2 | 0 | 1 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2013 to now |
| Beat AML | Lead sponsor of trials | 2016 to now |
| Concentra Biosciences | Lead sponsor of trials | 2021 to now |